Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

RCT (n=479, US) reports treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14 (median ordinal outcome score, 6 [4-7] vs 6 [4-7]; adjusted odds ratio, 1.02 [95% CI, 0.73 to 1.42]).

SPS commentary:

Authors’ of a related editorial state several lessons are to be gained from the experience with hydroxychloroquine in the treatment of COVID-19. First, a single report based on a small, nonrandomized study must be considered preliminary and hypothesis generating, not clinically actionable. Likewise, anecdotal case reports and case series that include several cases likewise must be considered anecdotal and preliminary. Authors’ state for other potential therapies or interventions for COVID-19 (or any other diseases), this should not happen again.

Source:

Journal of the American Medical Association

Resource links:

Editorial